Literature DB >> 17059222

Multiple steps determine the overall rate of the reduction of 5alpha-dihydrotestosterone catalyzed by human type 3 3alpha-hydroxysteroid dehydrogenase: implications for the elimination of androgens.

Yi Jin1, Trevor M Penning.   

Abstract

Human type 3 3alpha-hydroxysteroid dehydrogenase, or aldo-keto reductase (AKR) 1C2, eliminates the androgen signal in human prostate by reducing 5alpha-dihydrotestosterone (DHT, potent androgen) to form 3alpha-androstanediol (inactive androgen), thereby depriving the androgen receptor of its ligand. The k(cat) for the NADPH-dependent reduction of DHT catalyzed by AKR1C2 is 0.033 s(-1). We employed transient kinetics and kinetic isotope effects to dissect the contribution of discrete steps to this low k(cat) value. Stopped-flow experiments to measure the formation of the AKR1C2.NADP(H) binary complex indicated that two slow isomerization events occur to yield a tight complex. A small primary deuterium isotope effect on k(cat) (1.5) and a slightly larger effect on k(cat)/K(m) (2.1) were observed in the steady state. In the transient state, the maximum rate constant for the single turnover of DHT (k(trans)) was determined to be 0.11 s(-1) for the NADPH-dependent reaction, which was approximately 4-fold greater than the corresponding k(cat) x k(trans) was significantly reduced when NADPD was substituted for NADPH, resulting in an apparent (D)k(trans) of 3.5. Thus, the effects of isotopic substitution on the hydride transfer step were masked by slow events that follow or precede the chemical transformation. Transient multiple-turnover reactions generated curvilinear reaction traces, consistent with the product formation and release occurring at comparable rates. Global fitting analysis of the transient kinetic data enabled the estimate of the rate constants for the three-step cofactor binding/release model and for the minimal ordered bi-bi turnover mechanism. Results were consistent with a kinetic mechanism in which a series of slow events, including the chemical step (0.12 s(-1)), the release of the steroid product (0.081 s(-1)), and the release of the cofactor product (0.21 s(-1)), combine to yield the overall observed low turnover number.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059222      PMCID: PMC2597410          DOI: 10.1021/bi060591r

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  40 in total

1.  Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.

Authors:  T M Penning; M E Burczynski; J M Jez; C F Hung; H K Lin; H Ma; M Moore; N Palackal; K Ratnam
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

2.  Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2).

Authors:  John W Trauger; Alice Jiang; Brian A Stearns; Philip V LoGrasso
Journal:  Biochemistry       Date:  2002-11-12       Impact factor: 3.162

3.  Molecular docking simulations of steroid substrates into human cytosolic hydroxysteroid dehydrogenases (AKR1C1 and AKR1C2): insights into positional and stereochemical preferences.

Authors:  Yi Jin; Trevor M Penning
Journal:  Steroids       Date:  2006-02-07       Impact factor: 2.668

4.  Structure of the human 3alpha-hydroxysteroid dehydrogenase type 3 in complex with testosterone and NADP at 1.25-A resolution.

Authors:  V Nahoum; A Gangloff; P Legrand; D W Zhu; L Cantin; B S Zhorov; V Luu-The; F Labrie; R Breton; S X Lin
Journal:  J Biol Chem       Date:  2001-08-20       Impact factor: 5.157

5.  Transient-state and steady-state kinetic studies of the mechanism of NADH-dependent aldehyde reduction catalyzed by xylose reductase from the yeast Candida tenuis.

Authors:  B Nidetzky; M Klimacek; P Mayr
Journal:  Biochemistry       Date:  2001-08-28       Impact factor: 3.162

6.  Examination of the differences in structure-function of human and rat 3alpha-hydroxysteroid dehydrogenase.

Authors:  Yi Jin; William C Cooper; Trevor M Penning
Journal:  Chem Biol Interact       Date:  2003-02-01       Impact factor: 5.192

7.  The aldo-keto reductase superfamily homepage.

Authors:  David Hyndman; David R Bauman; Vladi V Heredia; Trevor M Penning
Journal:  Chem Biol Interact       Date:  2003-02-01       Impact factor: 5.192

8.  Structure of xylose reductase bound to NAD+ and the basis for single and dual co-substrate specificity in family 2 aldo-keto reductases.

Authors:  Kathryn L Kavanagh; Mario Klimacek; Bernd Nidetzky; David K Wilson
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

Review 9.  Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action.

Authors:  Trevor M Penning
Journal:  Hum Reprod Update       Date:  2003 May-Jun       Impact factor: 15.610

10.  Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.

Authors:  Tea Lanisnik Rizner; Hsueh K Lin; Donna M Peehl; Stephan Steckelbroeck; David R Bauman; Trevor M Penning
Journal:  Endocrinology       Date:  2003-07       Impact factor: 4.736

View more
  33 in total

Review 1.  Human hydroxysteroid dehydrogenases and pre-receptor regulation: insights into inhibitor design and evaluation.

Authors:  Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2011-01-25       Impact factor: 4.292

Review 2.  The syndrome of 17,20 lyase deficiency.

Authors:  Walter L Miller
Journal:  J Clin Endocrinol Metab       Date:  2011-11-09       Impact factor: 5.958

3.  Oxidation of dihydrotestosterone by human cytochromes P450 19A1 and 3A4.

Authors:  Qian Cheng; Christal D Sohl; Francis K Yoshimoto; F Peter Guengerich
Journal:  J Biol Chem       Date:  2012-07-07       Impact factor: 5.157

Review 4.  Identification of the molecular switch that regulates access of 5alpha-DHT to the androgen receptor.

Authors:  Trevor M Penning; David R Bauman; Yi Jin; Tea Lanisik Rizner
Journal:  Mol Cell Endocrinol       Date:  2007-01-16       Impact factor: 4.102

Review 5.  The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.

Authors:  Oleg A Barski; Srinivas M Tipparaju; Aruni Bhatnagar
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

6.  Specificity of human aldo-keto reductases, NAD(P)H:quinone oxidoreductase, and carbonyl reductases to redox-cycle polycyclic aromatic hydrocarbon diones and 4-hydroxyequilenin-o-quinone.

Authors:  Carol A Shultz; Amy M Quinn; Jong-Heum Park; Ronald G Harvey; Judy L Bolton; Edmund Maser; Trevor M Penning
Journal:  Chem Res Toxicol       Date:  2011-09-29       Impact factor: 3.739

7.  Characterization of disease-related 5beta-reductase (AKR1D1) mutations reveals their potential to cause bile acid deficiency.

Authors:  Jason E Drury; Rebekka Mindnich; Trevor M Penning
Journal:  J Biol Chem       Date:  2010-06-03       Impact factor: 5.157

Review 8.  Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes.

Authors:  Trevor M Penning; Phumvadee Wangtrakuldee; Richard J Auchus
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

9.  An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.

Authors:  Michael C Byrns; Stephan Steckelbroeck; Trevor M Penning
Journal:  Biochem Pharmacol       Date:  2007-09-14       Impact factor: 5.858

10.  Catalytic mechanism and substrate specificity of the beta-subunit of the voltage-gated potassium channel.

Authors:  Srinivas M Tipparaju; Oleg A Barski; Sanjay Srivastava; Aruni Bhatnagar
Journal:  Biochemistry       Date:  2008-08-02       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.